TBK1 inhibitors: a review of patent literature (2011 – 2014)

Bibliography

• Fitzgerald KA, McWhirter SM, Faia KL, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003;4:491-6
   PubMed Web of Science ®Google Scholar
• Shu C, Sankaran B, Chaton CT, et al. Structural insights into the functions of TBK1 in innate antimicrobial immunity. Structure 2013;21:1137-48
   PubMed Web of Science ®Google Scholar
• Baccala R, Hoebe K, Kono DH, et al. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007;13:543-51
   PubMed Web of Science ®Google Scholar
• Chen G, Shaw MH, Kim YG, Nunez G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol 2009;4:365-98
   PubMed Web of Science ®Google Scholar
• Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 2008;26:535-84
   PubMed Web of Science ®Google Scholar
• Zhong B, Yang Y, Li S, et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity 2008;29:538-50
   PubMed Web of Science ®Google Scholar
• Li Z, Liu G, Sun L, et al. PPM1A Regulates antiviral signaling by antagonizing TBK1-mediated STING phosphorylation and aggregation. PLoS Pathog 2015;11:e1004783
   PubMed Web of Science ®Google Scholar
• Wang Q, Liu X, Cui Y, et al. The E3 ubiquitin ligase AMFR and INSIG1 bridge the activation of TBK1 kinase by modifying the adaptor STING. Immunity 2014;41:919-33
   PubMed Web of Science ®Google Scholar
• Kim SS, Lee KG, Chin CS, et al. DOK3 is required for IFN-beta production by enabling TRAF3/TBK1 complex formation and IRF3 activation. J Immunol 2014;193:840-8
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhao X, Zhang M, et al. Ubiquitin-specific protease 2b negatively regulates IFN-beta production and antiviral activity by targeting TANK-binding kinase 1. J Immunol 2014;193:2230-7
   PubMed Web of Science ®Google Scholar
• Zhang L, Mo J, Swanson KV, et al. NLRC3, a member of the NLR family of proteins, is a negative regulator of innate immune signaling induced by the DNA sensor STING. Immunity 2014;40:329-41
   PubMed Web of Science ®Google Scholar
• Yu T, Yi YS, Yang Y, et al. The pivotal role of TBK1 in inflammatory responses mediated by macrophages. Mediators Inflamm 2012;2012:979105
   PubMed Web of Science ®Google Scholar
• Larabi A, Devos JM, Ng SL, et al. Crystal structure and mechanism of activation of TANK-binding kinase 1. Cell Rep 2013;3:734-46
   PubMed Web of Science ®Google Scholar
• Tu D, Zhu Z, Zhou AY, et al. Structure and ubiquitination-dependent activation of TANK-binding kinase 1. Cell Rep 2013;3:747-58
   PubMed Web of Science ®Google Scholar
• Ryzhakov G, Randow F. SINTBAD, a novel component of innate antiviral immunity, shares a TBK1-binding domain with NAP1 and TANK. EMBO J 2007;26:3180-90
   PubMed Web of Science ®Google Scholar
• Muvaffak A, Pan Q, Yan H, et al. Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. Mol Cancer Res 2014;12:1055-66
   PubMed Web of Science ®Google Scholar
• Chien Y, Kim S, Bumeister R, et al. RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 2006;127:157-70
   PubMed Web of Science ®Google Scholar
• Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462:108-12
   PubMed Web of Science ®Google Scholar
• Kim JK, Jung Y, Wang J, et al. TBK1 regulates prostate cancer dormancy through mTOR inhibition. Neoplasia 2013;15:1064-74
   PubMed Web of Science ®Google Scholar
• Jiang Z, Liu JC, Chung PE, et al. Targeting HER2(+) breast cancer: the TBK1/IKKepsilon axis. Oncoscience 2014;1:180-2
   PubMedGoogle Scholar
• Yang KM, Jung Y, Lee JM, et al. Loss of TBK1 induces epithelial-mesenchymal transition in the breast cancer cells by ERalpha downregulation. Cancer Res 2013;73:6679-89
   PubMed Web of Science ®Google Scholar
• Deng T, Liu JC, Chung PE, et al. shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer. Cancer Res 2014;74:2119-30
   PubMed Web of Science ®Google Scholar
• Liu W, Huang YJ, Liu C, et al. Inhibition of TBK1 attenuates radiation-induced epithelial-mesenchymal transition of A549 human lung cancer cells via activation of GSK-3beta and repression of ZEB1. Lab Invest 2014;94:362-70
   PubMed Web of Science ®Google Scholar
• Kim JY, Welsh EA, Oguz U, et al. Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci USA 2013;110:12414-19
   PubMed Web of Science ®Google Scholar
• Migita K, Nakamura T. TBK1: a potential therapeutic target in RA. Rheumatology (Oxford) 2012;51:588-9
   PubMed Web of Science ®Google Scholar
• Yu J, Zhou X, Chang M, et al. Regulation of T-cell activation and migration by the kinase TBK1 during neuroinflammation. Nat Commun 2015;6:6074
   PubMed Web of Science ®Google Scholar
• Czabanka M, Korherr C, Brinkmann U, Vajkoczy P. Influence of TBK-1 on tumor angiogenesis and microvascular inflammation. Front Biosci 2008;13:7243-9
   PubMed Web of Science ®Google Scholar
• Yang Y, Lee GJ, Yoon DH, et al. ERK1- and TBK1-targeted anti-inflammatory activity of an ethanol extract of Dryopteris crassirhizoma. J Ethnopharmacol 2013;145:499-508
   PubMed Web of Science ®Google Scholar
• Clark K, Peggie M, Plater L, et al. Novel cross-talk within the IKK family controls innate immunity. Biochem J 2011;434:93-104
   PubMed Web of Science ®Google Scholar
• Minegishi Y, Iejima D, Kobayashi H, et al. Enhanced optineurin E50K-TBK1 interaction evokes protein insolubility and initiates familial primary open-angle glaucoma. Hum Mol Genet 2013;22:3559-67
   PubMed Web of Science ®Google Scholar
• Newman AC, Scholefield CL, Kemp AJ, et al. TBK1 kinase addiction in lung cancer cells is mediated via autophagy of Tax1bp1/Ndp52 and non-canonical NF-kappaB signalling. PLoS ONE 2012;7:e50672
   PubMed Web of Science ®Google Scholar
• Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010;115:5232-40
   PubMed Web of Science ®Google Scholar
• Zhu Z, Aref AR, Cohoon TJ, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov 2014;4:452-65
   PubMed Web of Science ®Google Scholar
• University court of the University of Dundee. Pyrimidine compounds for the treatment of cancer, septic shock and/or primary open angle glaucoma. WO030890; 2009
   Google Scholar
• Wang T, Block MA, Cowen S, et al. Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKepsilon kinases. Bioorg Med Chem Lett 2012;22:2063-9
   PubMed Web of Science ®Google Scholar
• Vu HL, Aplin AE. Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma. Mol Cancer Res 2014;12:1509-19
   PubMed Web of Science ®Google Scholar
• Richters A, Basu D, Engel J, et al. Identification and further development of potent TBK1 inhibitors. ACS Chem Biol 2015;10:289-98
   PubMed Web of Science ®Google Scholar
• Hutti JE, Porter MA, Cheely AW, et al. Development of a high-throughput assay for identifying inhibitors of TBK1 and IKKepsilon. PLoS ONE 2012;7:e41494
   PubMed Web of Science ®Google Scholar
• Li J, Huang J, Jeong JH, et al. Selective TBK1/IKKi dual inhibitors with anticancer potency. Int J Cancer 2014;134:1972-80
   PubMed Web of Science ®Google Scholar
• Domainex. Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK1, processes for their preparation, and pharmaceutical compositions containing them. WO010826; 2012
   Google Scholar
• Richards B, Cronin M, Seager N, et al. Cellular and in vivo properties of MPI-0485520, a novel and potent small molecule inhibitor of IKKe. FASEB J 2010;24(Meeting Abstract Suppl):753.6
   Google Scholar
• Myrexis. Amino-pyrimidine compounds as inhibitors of IKK epsilon and/or TBK1. WO0238540; 2012
   Google Scholar